Supporting accelerated growth of R&D, manufacturing, and
commercial activities with new 100,000 sq-ft state-of-the-art
facility
Reinforcing commitment to the region as Abcam approaches 20
years of US presence
CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM:
ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents
and tools, today announces the opening of a major new site in
Waltham, MA.
The new facility is a central component of Abcam's growth in
the United States, reinforcing its
commitment to support the research and biopharma sector globally
and serving as a hub for the Company's R&D and commercial
activities in the region.
"Abcam's first step toward global expansion was in 2003 at
Kendall Square. Since then, the US has become our largest
market." commented Alan
Hirzel, CEO at Abcam. "Investing in and expanding our
presence in the vibrant Greater
Boston cluster is another step in our journey to
support biopharma partners and life science researchers
globally, in their quest to accelerate discovery and the
translation of these discoveries into improved human health
outcomes."
The 100,000 sq-ft site will increase the Company's flexibility,
scale, and capacity in R&D, Production, Distribution, and
Customer Service required to address the increasing needs of the
life sciences sector. The ability to provide critical
reagents to support research in all areas of the life sciences is
vital to enable scientific breakthroughs that underpin the rapid
development of diagnostics, vaccines, and potential
therapeutics.
"Massachusetts continues to
attract life sciences companies from across the globe, who come
here to access our leading academic and medical institutions,
diverse talent, a supportive government, and a robust start-up
community," said Kendalle Burlin
O'Connell, president and COO at MassBio. "We are
thrilled to see Abcam outgrow its presence in Kendall Square and
expand to Waltham, an area of
growing interest for life sciences companies and one that is
positioned for explosive growth in the coming years."
This facility more than doubles Abcam's capacity from its
previous site in Kendall Square, Cambridge, MA and is expected to eventually
house approximately 300 employees. The opening follows Abcam's
listing on NASDAQ in October 2020 and
the establishment of its new cell engineering facility in the Bay
Area in December 2020.
Notes to Editors
About Abcam plc
As a global life sciences company,
Abcam identifies, develops, and distributes high-quality biological
reagents and tools that are crucial to research, drug discovery and
diagnostics. Working across the industry, the Company supports life
scientists to achieve their mission, faster.
Abcam partners with life sciences organizations to co-create
novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is
helping advance the global understanding of biology and causes of
disease, which enables new treatments and improved health. The
Company's pioneering data-sharing approach gives scientists
increased confidence in their results by providing validation, user
comments and peer-reviewed citations for its 90,000 products.
With 13 sites globally, many of Abcam's 1,600-strong team are
located in the world's leading life sciences research hubs,
complementing a global network of services and support.
To find out more, please visit www.abcam.com and
www.abcamplc.com.